Skip to main content

Advertisement

Table 4 Prognostic factors according to subgroup analysis

From: Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses

Variables Luminal A Luminal B HER2 TNBC
HR 95 % CI P HR 95 % CI P HR 95 % CI P HR 95 % CI P
Age             
  ≤ median 0.477 0.078–2.907 0.422 0.646 0.207–2.019 0.453 0.616 0.188–2.016 0.423 0.597 0.168–2.115 0.424
  > median 1    1    1    1   
Menopausal status             
 Premenopausal 0.092 0.009–0.906 0.041 0.875 0.282–2.727 0.818 0.482 0.132–1.754 0.268 0.741 0.214–2.558 0.635
 Postmenopausal 1    1    1    1   
pCR   -   0.039 0.000–46.767 0.370 0.360 0.047–2.773 0.327 0.420 0.053–3.323 0.411
vs non-pCR     1    1    1   
AJCC response             
 CR plus PR 0.078 0.008–0.778 0.030 0.157 0.050–0.499 0.002 0.221 0.058–0.838 0.026 0.219 0.061–0.783 0.020
 NR 1    1    1    1   
Pathologic Stage             
 yp0,I 0.517 0.247–1.081 0.080 0.160 0.021–1.238 0.079 0.162 0.036–0.732 0.018 0.182 0.038–0.861 0.032
 ypII, III, IV 1    1    1    1   
Surgery             
 BCS 0.414 0.069–2.493 0.336 0.329 0.101–1.071 0.065 0.296 0.081–1.081 0.065 0.930 0.240–3.660 0.917
 Mastectomy 1    1    1    1   
  1. pCR pathologic complete response, CR complete response, PR partial response, NR no response, BCS breast conserving surgery, HER2 human epidermal growth factor receptor 2, TNBC triple negative breast cancer, HR hazard ratio, 95 % CI 95 % confidence interval, P p-value